These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 30877177

  • 1. Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
    Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R.
    J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
    [Abstract] [Full Text] [Related]

  • 2. Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
    Valkema MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, Spaander MCW, Doukas M, Lagarde SM, Schreurs WMJ, Roef MJ, van Lanschot JJB, Valkema R.
    J Nucl Med; 2021 Apr; 62(4):486-492. PubMed ID: 32887759
    [Abstract] [Full Text] [Related]

  • 3. Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Xu X, Sun ZY, Wu HW, Zhang CP, Hu B, Rong L, Chen HY, Xie HY, Wang YM, Lin HP, Bai YR, Ye Q, Ma XM.
    Radiat Oncol; 2021 Jul 19; 16(1):132. PubMed ID: 34281566
    [Abstract] [Full Text] [Related]

  • 4. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study.
    Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, Lam MGEH, van Lier ALHMW, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ.
    Int J Radiat Oncol Biol Phys; 2020 Apr 01; 106(5):998-1009. PubMed ID: 31987972
    [Abstract] [Full Text] [Related]

  • 5. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment 18F-FDG PET/CT Imaging.
    Beukinga RJ, Hulshoff JB, van Dijk LV, Muijs CT, Burgerhof JGM, Kats-Ugurlu G, Slart RHJA, Slump CH, Mul VEM, Plukker JTM.
    J Nucl Med; 2017 May 01; 58(5):723-729. PubMed ID: 27738011
    [Abstract] [Full Text] [Related]

  • 6. 18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
    Valkema MJ, de Lussanet de la Sablonière QG, Valkema R, Thomeer MGJ, Dwarkasing RS, Harteveld AA, Doukas M, Mostert B, van der Zijden CJ, van der Sluis PC, Lagarde SM, Wijnhoven BPL, Verburg FA, van Lanschot JJB.
    Nucl Med Commun; 2024 Feb 01; 45(2):128-138. PubMed ID: 37982560
    [Abstract] [Full Text] [Related]

  • 7. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.
    Clin Nucl Med; 2014 Oct 01; 39(10):862-7. PubMed ID: 25140549
    [Abstract] [Full Text] [Related]

  • 8. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer.
    Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart RHJA, Plukker JTM.
    Radiology; 2018 Jun 01; 287(3):983-992. PubMed ID: 29533721
    [Abstract] [Full Text] [Related]

  • 9. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
    Eyck BM, Onstenk BD, Noordman BJ, Nieboer D, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB.
    Ann Surg; 2020 Feb 01; 271(2):245-256. PubMed ID: 31188203
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A, Chaudhry M, Blakeley JO, Wahl R.
    J Nucl Med; 2015 Mar 01; 56(3):379-85. PubMed ID: 25655626
    [Abstract] [Full Text] [Related]

  • 11. 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.
    Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S.
    J Nucl Med; 2019 Nov 01; 60(11):1560-1568. PubMed ID: 30877175
    [Abstract] [Full Text] [Related]

  • 12. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB, SANO study group.
    Lancet Oncol; 2018 Jul 01; 19(7):965-974. PubMed ID: 29861116
    [Abstract] [Full Text] [Related]

  • 13. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C, Niccoli Asabella A, De Luca R, Fanelli M, Caliandro C, Quartuccio N, Rubini D, Cistaro A, Montemurro S, Rubini G.
    Abdom Imaging; 2015 Jun 01; 40(5):1190-202. PubMed ID: 25348731
    [Abstract] [Full Text] [Related]

  • 14. Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer.
    Kroese TE, Ruurda JP, Bakker AS, Jairam J, Mook S, van der Horst S, Meijer GJ, Haj Mohammad N, van Rossum PSN, van Hillegersberg R.
    Clin Nucl Med; 2022 Jun 01; 47(6):496-502. PubMed ID: 35384907
    [Abstract] [Full Text] [Related]

  • 15. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW, Zheng RL, Ling YH, Wang QX, Xiao WW, Zeng ZF, Fan W, Li LR, Gao YH.
    Abdom Radiol (NY); 2016 Aug 01; 41(8):1448-55. PubMed ID: 27116012
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.
    Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.
    BMC Med Imaging; 2017 Jan 05; 17(1):1. PubMed ID: 28056868
    [Abstract] [Full Text] [Related]

  • 19. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
    van der Bogt RD, Noordman BJ, Krishnadath KK, Roumans CAM, Schoon EJ, Oostenbrug LE, Siersema PD, Vleggaar FP, van Lanschot JJB, Spaander MCW.
    Endoscopy; 2019 Apr 05; 51(4):326-332. PubMed ID: 30497088
    [Abstract] [Full Text] [Related]

  • 20. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
    Koç M, Kaya GÇ, Demir Y, Sürücü E, Sarioğlu S, Obuz F, Öztop İ, Görken İB, Sökmen S.
    Nucl Med Commun; 2015 Sep 05; 36(9):898-907. PubMed ID: 25969176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.